The Low-Concentration Atropine for Myopia Progression (LAMP) Study has provided invaluable data on comparisons between 0.05%, 0.025% and 0.01% atropine treatment. The three year data has shown 0.05% to be most effective for continued treatment, while children discontinued showed a small, ‘clinically insignificant’ rebound effect. Learn more about the one, two and three year LAMP data here.
This meta-analysis of 5 studies of 1, 6 and 12 months duration found that slower axial growth is evident when using orthokeratology in conjunction with atropine as a combined therapy compared to orthokeratology alone. A slowing effect of 0.09mm was seen with the combined approach for up to a 12 month follow-up period. Longer data was not available for the meta-analysis.
This research showed that the concentration of atropine which reaches the retina is 400 times less than by topical administration; and that higher concentrations directly exposed to the mouse retina influence retinal signaling. Whether this is indicates a possible mechanism or unintended impact of atropine, and how this may translate to atropine use in humans, is unknown.
Despite being used for myopia management for many years, significant controversy exists in both literature and clinical optometric practice regarding the optimal concentration of atropine. The LAMP study sheds light on this mystery by investigating efficacy of 0.05%, 0.025% and 0.01% atropine for slowing myopia progression.
Pathologic myopia is one of the major causes of blindness worldwide. Degenerative changes associated with high myopia, including posterior staphyloma formation and scleral thinning, are caused by the progressive elongation of globe axial length and stretching of the sclera, choroid and retina. The aim of this meta-analysis was to investigate and quantitatively define the efficacy of PSR in controlling axial elongation and refraction progression.
In myopia development the sclera is at risk of deformation due to increasing axial length progression. This research investigates whether cross-linking treatment could be used to stiffen the sclera as a way to restrict axial eye elongation.
The atropine landscape is constantly evolving as new studies are published. Here is a compiled summary of all of the most recent atropine eye drop studies for myopia control, along with information on trials currently underway.
Welcome to Part 2 of the updates from the American Academy of Optometry 2019 Meeting. These updates all sprung from Mark Bullimore and Noel Brennan’s fantastic session entitled Twelve Evidence Based Things That We Should Know About Myopia.
Welcome to Part 2 of the ARVO 2019 Research Roundup! For article abstracts and more info, please click on the headings.
Three more fascinating areas and/or pieces of research presented at IMC, and some bonus material.
